Associated Papers
FGFR Testing in Metastatic Urothelial Carcinoma-Who, When, and How to Test.
Mansinho A et al.
Cancers, 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Association of phosphorylation status of ERK and genetic MAPK alterations in pediatric tumors.
Selt F et al.
Scientific Reports, 2025
Non-small cell lung carcinoma with clear cell features: a clinicopathologic, immunohistochemical, and molecular study of 31 cases.
Suster DI et al.
Virchows Archiv : an International Journal of Pathology, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors.
Kim M et al.
Cancer Research and Treatment, 2023
The landscape of actionable genomic alterations in lung adenocarcinomas in India.
Sharma R et al.
Frontiers in Genetics, 2023
Discovery of 2-Amino-7-sulfonyl-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Potent Reversible FGFR Inhibitors with Gatekeeper Mutation Tolerance: Design, Synthesis, and Biological Evaluation.
Xie W et al.
Journal of Medicinal Chemistry, 2022
Targeting Gatekeeper Mutations for Kinase Drug Discovery.
Zhou Y et al.
Journal of Medicinal Chemistry, 2022
Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select.
Niu Y et al.
Nature Genetics, 2022
Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors.
Yang F et al.
Journal of Medicinal Chemistry, 2022
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.
Kohsaka S et al.
Npj Precision Oncology, 2022
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.
Lin Q et al.
Communications Chemistry, 2022
Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer.
Moes-Sosnowska J et al.
Frontiers in Oncology, 2022
Intrinsic relative preference profile of pan-kinase inhibitor drug staurosporine towards the clinically occurring gatekeeper mutations in Protein Tyrosine Kinases.
Ren Z et al.
Computational Biology and Chemistry, 2021
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M et al.
Expert Review of Clinical Pharmacology, 2021
Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites.
Cha S et al.
Npj Breast Cancer, 2021
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA.
Finkle JD et al.
Npj Precision Oncology, 2021
Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas.
Juan Ribelles A et al.
Journal of Personalized Medicine, 2021
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Krook MA et al.
British Journal of Cancer, 2021
FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM et al.
Pharmacology & Therapeutics, 2020
Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4.
Zhou Z et al.
Chemical Communications (cambridge, England), 2019
LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance.
Wu D et al.
Chemical Communications (cambridge, England), 2018
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS et al.
Cancer, 2016
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
International Journal of Molecular Medicine, 2016
Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.
Patani H et al.
Oncotarget, 2016
Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.
Gallo LH et al.
Cytokine & Growth Factor Reviews, 2015
Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.
Ang D et al.
Applied Immunohistochemistry & Molecular Morphology : Aimm, 2015
Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
Tucker JA et al.
Structure (london, England : 1993), 2014
Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Dixit A et al.
Computational and Mathematical Methods in Medicine, 2014
High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis.
Paulson V et al.
Genes, Chromosomes & Cancer, 2011